TCRX Tscan Therapeutics Inc
Company Analysis
Latest News
🔴 Tscan Therapeutics Falls 13.26% as Analysts Downgrade Stock Following Strategic Reorganization and ALLOHA-2 Pause
Tscan Therapeutics is trading lower at $0.34 (-13.26%) on September 8, 2026, following downgrades by analysts including H.C. Wainwright and Wedbush. * This...
🔴 Tscan Therapeutics is trading 7.46% down today
Tscan Therapeutics is trading 7.46% down at $0.36, with the catalyst for the decline unclear. - No new company-specific announcement dated September 8, 2026...
🟢 Tscan Therapeutics is trading 5% up in pre-market in an unexplained rebound
Tscan Therapeutics is trading 5.01% up at $0.41 in pre-market pricing, following a sharp decline earlier in the week; the rebound is unexplained and low...
🟢 Tscan Therapeutics is trading 5% up today recovering after strategic reorganization selloff
Tscan Therapeutics is trading 5.31% up at $0.39 after a modest recovery from the sharp selloff triggered by its September 2, 2026 strategic reorganization...
🟢 Tscan Therapeutics is trading 6.23% up today following sharp selloff
Tscan Therapeutics is trading 6.23% up at $0.39, recovering modestly after the sharp selloff that followed its September 2, 2026 announcement. - The company...
🔴 Tscan Therapeutics is trading 6.27% down today after pausing Phase 3 ALLOHA-2 enrollment over insufficient capital
Tscan Therapeutics is trading 6.27% down at $0.36 after pausing further Phase 3 ALLOHA-2 enrollment because of insufficient capital. - On September 2, 2026,...
🔴 Tscan Therapeutics is trading 5.4% down in pre-market after pausing Phase 3 ALLOHA-2 enrollment
Tscan Therapeutics is trading 5.4% down in pre-market at $0.36 after announcing on September 2, 2026, that it would pause further enrollment in the Phase 3...
TScan Therapeutics Announces Restructuring, Cuts 75% of Workforce to Focus on Solid Tumors
TScan Therapeutics announced a significant strategic reorganization to prioritize its preclinical in vivo solid tumor program and extend its cash runway. The...
TScan Slashes 75% of Its Staff and Freezes Its Most Advanced Trial — Can a Pivot to Solid Tumors Save a Sub-$1 Stock?
Shares of TScan Therapeutics (TCRX) cratered 25.7% to $0.49 on September 2 after the Waltham, Mass., biotech announced it would gut three-quarters of its...
🔴 Tscan Therapeutics is trading 26% down today after pausing Phase 3 ALLOHA-2 enrollment
Tscan Therapeutics is trading 25.71% down now at $0.49 after announcing a strategic reorganization on September 2, 2026, including a pause in Phase 3 ALLOHA-2...
TScan Therapeutics Slashes Staff by 75%, Prioritizing Solid Tumor Pipeline
TScan Therapeutics is cutting its workforce by approximately 75% to prioritize its in vivo solid tumor program. The company is currently advancing two product...
🔴 Tscan Therapeutics is trading 14% down in pre-market
Tscan Therapeutics is trading at $0.57, down -13.72%, with no clear company-specific catalyst identified for September 2, 2026. - No fresh company-specific...
🔴 Tscan Therapeutics is trading 8.43% down in pre-market with no fresh company-specific catalyst
Tscan Therapeutics is trading at $0.61, down -8.43% in pre-market, with no fresh company-specific catalyst identified for September 2, 2026. - The latest...
🟢 Tscan Therapeutics is trading 5.7% up in pre-market
Tscan Therapeutics is trading at $0.70, up +5.67% in pre-market, with no fresh company-specific catalyst identified. - No announcement, earnings release, or...
🔴 Tscan Therapeutics Inc is trading 5.69% down
TCRX is trading at $0.69, down 5.69%.
🟢 Tscan Therapeutics is trading 5% up today amid volatility, with no confirmed catalyst
Tscan Therapeutics is trading 5.13% up now at $0.79, with the move appearing primarily volatility-driven rather than tied to a confirmed fundamental...
🟢 Tscan Therapeutics is trading 5% up in after-hours trading amid volatility after prior selloff
Tscan Therapeutics is trading at $0.79, up +5.04% in after-hours trading; the move may reflect volatility after the prior selloff, as no separate bullish...
🔴 Tscan Therapeutics is trading 6.21% down today after Amgen terminated collaboration and license agreement
Tscan Therapeutics is trading 6.21% down at $0.77 after an August 18, 2026 filing disclosed that Amgen elected to terminate its research collaboration and...
🔴 Tscan Therapeutics is trading 5.4% down in pre-market amid elevated Treasury yields
Tscan Therapeutics is trading 5.42% down now at $0.78 as broader risk-off pressure weighs on growth-oriented stocks. - No new company-specific announcement,...
🔴 Tscan Therapeutics is trading 5.53% down in after-hours trading as rising Treasury yields pressure growth stocks
Tscan Therapeutics is trading 5.53% down now at $0.78 as broad risk-off selling pressures U.S. equities on August 18, 2026. - No new company-specific...